Public RelationsBiond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 ReceptorApril 26, 2021Biond Biologics Announces Global Licensing Agreement with Sanofi for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 ReceptorJanuary 12, 2021Biond Biologics Announces Poster Presentations at AACR 2020 Virtual Annual MeetingJune 9, 2020Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate UpdateJune 1, 2020Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory BoardNovember 25, 2019Biond Biologics Annual Company Gathering | Misgav Industrial ParkMay 12, 2019Biond Biologics Announces $17 Million FinancingJanuary 8, 2019
